Introduction {#section1-1534735418816825}
============

Pancreatic cancer is one of the most lethal malignancies among major solid tumors.^[@bibr1-1534735418816825]^ There has been little improvement of oncologic outcomes even after implementation of various therapeutic approaches.^[@bibr2-1534735418816825][@bibr3-1534735418816825]-[@bibr4-1534735418816825]^ Surgical resection with curative intent, followed by adjuvant chemotherapy, is the only therapeutic option that has demonstrated long-term survival without tumor recurrence in pancreatic cancer.^[@bibr5-1534735418816825],[@bibr6-1534735418816825]^ Current evidence indicates that adherence and completion of adjuvant treatment after radical pancreatectomy are crucial factors for improved oncologic outcomes.^[@bibr7-1534735418816825]^ However, there is limited research evaluating potential methods for improving adherence to adjuvant treatment after curative resection of pancreatic cancer. We previously published our interim results for potential clinical application of *Phellinus linteus* (PL) in treatment of pancreatic cancer.^[@bibr8-1534735418816825]^ In this study, based on accumulating clinical data, we attempted to perform further analysis to identify the potential role of PL medication in patients who underwent radical pancreatectomy for pancreatic ductal adenocarcinoma.

Methods {#section2-1534735418816825}
=======

Study Design {#section3-1534735418816825}
------------

This study is a retrospective cohort clinical study based on a single institutional database. From January 1995 to December 2014, 323 patients with pancreatic cancer who underwent pancreatectomy at the Severance Hospital were enrolled in this study. We retrospectively collected and analyzed data regarding clinicopathologic factors, including demographics, perioperative management, short-term outcomes, and administration of PL medication of the patients from our institutional pancreatic cancer cohort. Oncologic outcomes, including recurrences and cancer-related death, were obtained from medical records. This study was approved by the institutional review board of the Severance Hospital, Seoul, Korea (2017-1566-001).

*Phellinus linteus* Extract Medication {#section4-1534735418816825}
--------------------------------------

PL is a medical mushroom that has been used in East Asia for centuries to manage several diseases; its extract, which contains various bioactive substances, including proteoglycans, polysaccharides, cyclophellitol, hispidin, furan derivatives, and hispolon,^[@bibr9-1534735418816825]^ was commercialized as an oral medication in Korea, and it has been administered to pancreatic cancer patients who underwent curative intent pancreatectomy since 2005 to enhance postoperative recovery. PL Mycelium Extract (Aclang, Kwangdong Pharmaceutical Co, Ltd, Korea), which was approved by the Korean Food & Drug Administration (KFDA), was administered at a dose of 1100 mg 3 times per day orally, after acquiring the informed consent of enrolled patients.

Clinical Setting for PL Medication After Curative Resection of Pancreatic Ductal Adenocarcinoma {#section5-1534735418816825}
-----------------------------------------------------------------------------------------------

PL medication has been prescribed as a supplementary drug to promote general health for postoperative patients who underwent radical pancreatectomy by a surgical oncologist ([Figure 3](#fig3-1534735418816825){ref-type="fig"}). This drug was administered only after the patient was provided detailed information about the drug and consented to its use. The administration of medication continued for the duration the patient agreed to continue adjuvant treatment for pancreatic cancer.

Propensity Score Matching {#section6-1534735418816825}
-------------------------

To reduce statistical selection bias in this retrospective study, propensity score matching was used for the comparisons in both the adjuvant treatment group, and no adjuvant treatment group. Major confounding factors for administering PL medication in each group were selected and propensity scores were measured by logistic regression. Proper matching procedures were performed in each group with nearest selection methods (1:1 matching in adjuvant group and 1:2 matching in no adjuvant group).

Statistics {#section7-1534735418816825}
----------

Comparisons between the 2 separate groups were conducted by statistical tests using Student's *t* test or Wilcoxon rank sum test for continuous variables, and chi-square test or Fisher's exact test for categorical variables. Survival analysis was performed using the Kaplan-Meier method, and log-rank test was used for comparisons of survival differences between the 2 groups. Cox's proportional hazard model was used to evaluate prognostic factors for recurrence and cancer-related death, and a logistic regression model was applied to estimate predictive variables for the completion of adjuvant treatment after curative resection of pancreatic cancer. A *P* value less than .05 was considered statistically significant.

Results {#section8-1534735418816825}
=======

Enrolled Patients {#section9-1534735418816825}
-----------------

The total study population was 217, after excluding patients who underwent neoadjuvant treatment or palliative resection, those who died within 30 days of resection, and those lost to follow-up after discharge ([Figure 1](#fig1-1534735418816825){ref-type="fig"}). Of the total study population, 161 patients received adjuvant treatment after curative resection, and 56 patients did not receive adjuvant treatment due to various reasons, including patient preference and an early stage cancer diagnosis, which insurance did not cover. The number of patients with PL medication was 68 in the group of adjuvant treatment and 15 in the no adjuvant treatment group. There was no adverse event related to PL medication during follow-up. Propensity score matching was performed for the groups with or without adjuvant treatment (1:1 matching in group with adjuvant treatment, 1:2 matching in group without adjuvant treatment).

![Flow diagram of the study cohort of pancreatic ductal adenocarcinoma patients.](10.1177_1534735418816825-fig1){#fig1-1534735418816825}

Prognostic Factors for Recurrence and Cancer-Related Death {#section10-1534735418816825}
----------------------------------------------------------

Cox's proportional hazard models were analyzed to evaluate major prognostic factors for recurrence and cancer-related death ([Table 1](#table1-1534735418816825){ref-type="table"}). Univariate and multivariate analysis revealed that tumor size, nodal metastasis, perioperative transfusion, and completion of adjuvant treatment were significantly correlated with cancer recurrence and cancer-related death (*P* \< .05).

###### 

Univariate and Multivariate Regression Model for Recurrence and Cancer-Related Death by Using Cox's Proportional Hazard Model in Total Study Population (n = 217).

![](10.1177_1534735418816825-table1)

  Variables                                                             Recurrence            Cancer-Related Death                                                                                     
  --------------------------------------------------------------------- --------------------- ---------------------- --------------------- ------ ----------------------- ------ --------------------- ------
  Patient characteristics                                                                                                                                                                              
   Age (years)                                                          0.996 (0.978-1.014)   .666                                                1.003 (0.983-1.023)     .763                         
   Sex (male/female)                                                    0.934 (0.671-1.299)   .683                                                1.144 (0.799-1.637)     .462                         
   BMI (kg/m^2^)                                                        1.003 (0.988-1.019)   .664                                                0.963 (0.911-1.018)     .186                         
   ASA score (1-2/3-4)                                                  1.278 (0.844-1.934)   .247                                                1.029 (0.477-1.563)     .894                         
   Comorbidity (yes/no)                                                 0.983 (0.673-1.435)   .928                                                1.183 (0.786-1.779)     .421                         
  Pathologic factors                                                                                                                                                                                   
   Tumor location (Head-Neck/Body-Tail)                                 1.143 (0.699-1.868)   .594                                                1.033 (0.931-1.149)     .542                         
   Tumor size (cm)                                                      1.197 (1.072-1.338)   .001                   1.211 (1.074-1.365)   .002   1.123 (0.992-1.272)     .066                         
   T stage (1-2/3-4)                                                    2.483 (0.997-5.357)   .087                                                1.105 (0.699-1.745)     .671                         
   Nodal metastasis (yes/no)                                            1.931 (1.361-2.738)   .001                   1.866 (1.288-2.704)   .001   1.872 (1.286-2.719)     .001   2.122 (1.292-3.486)   .003
   Cell differentiation (well and moderate/poor and undifferentiated)   1.787 (0.907-3.520)   .093                                                1.282 (0.931-1.766)     .128                         
   Perineural invasion (yes/no)                                         0.967 (0.684-1.367)   .851                                                0.927 (0.645-1.333)     .684                         
   Lymphovascular invasion (yes/no)                                     1.207 (0.859-1.697)   .278                                                1.165 (0.811-1.674)     .408                         
   R status (R0/R1-2)                                                   1.201 (0.755-1.909)   .439                                                1.280 (0.776-2.114)     .334                         
  Perioperative factors                                                                                                                                                                                
   Operation method (open/MIS)                                          1.354 (0.891-1.984)   .243                                                1.054 (0.978-1.024)     .458                         
   Intraoperative bleeding (mL)                                         1.001 (0.999-1.011)   .122                                                1.125 (0.997 - 1.548)   .265                         
   Perioperative transfusion (yes/no)                                   1.469 (0.999-2.160)   .051                   1.464 (0.992-2.160)   .055   1.781 (1.191 - 2.661)   .005   1.791 (1.112-2.881)   .017
   Postoperative major complication (yes/no)                            0.836 (0.517-1.353)   .466                                                0.803 (0.492-1.311)     .381                         
  Postoperative factors                                                                                                                                                                                
   Adjuvant treatment (yes/no)                                          0.829 (0.572-0.998)   0.048                  0.673 (0.456-0.995)   .047   0.775 (0.524-0.985)     .042   0.487 (0.342-0.876)   .001
   Completion without dose reduction (yes/no)                           0.863 (0.547-1.012)   .107                                                0.841 (0.642-0.947)     .048   0.251 (0.251-0.925)   .038
   *Phellinus linteus* medication (yes/no)                              1.024 (0.734-1.429)   .889                                                0.772 (0.534-1.116)     .168                         
   *Phellinus linteus* medication duration (weeks)                      1.003 (0.999-1.015)   .695                                                0.993 (0.974-1.012)     .449                         

Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index; CI, confidence interval; HR, hazard ratio; MIS, minimally invasive surgery.

Survival Analysis According to Adjuvant Treatment {#section11-1534735418816825}
-------------------------------------------------

The provision of adjuvant treatment was a major prognostic factor for disease-free and cancer-specific overall survival ([Figure 2](#fig2-1534735418816825){ref-type="fig"}). The group with adjuvant treatment showed significantly better survival outcomes than the group with no adjuvant treatment (*P* \< .05). Completion of adjuvant treatment was an especially important predictor for survival outcomes in the group with adjuvant treatment (*P* = .001).

![Survival analysis of the total population (n=217) and adjuvant treatment group (n = 161) after curative resection of pancreatic ductal adenocarcinoma.](10.1177_1534735418816825-fig2){#fig2-1534735418816825}

Predictive Factors for Completion of Adjuvant Treatment {#section12-1534735418816825}
-------------------------------------------------------

Logistic regression analysis was performed to evaluate the predictors for completion of adjuvant treatment after radical pancreatectomy ([Table 2](#table2-1534735418816825){ref-type="table"}). PL medication and several perioperative factors, including operation time, intraoperative bleeding, and postoperative major complications more than grade IV according to the Clavien-Dindo classification system, were revealed as significant factors in univariate analysis (*P* \< .05). However, PL medication was the only significant predictor for completion of adjuvant treatment after curative resection in multivariate analysis (adjusted odds ratio \[OR\] 2.141, 95% CI 1.039-4.411, *P* = .039).

###### 

Predictors for Completion of Adjuvant Treatment After Curative Resection of PDAC Using Logistic Regression Analysis in Adjuvant Treatment Group (n=161).

![](10.1177_1534735418816825-table2)

  Covariates                                         Crude OR   95% CI        *P*     Adjusted OR   95% CI        *P*
  -------------------------------------------------- ---------- ------------- ------- ------------- ------------- -------
  Patient characteristics                                                                                         
   Age (years)                                       1.004      0.972-1.038   0.797                               
   Sex (male/female)                                 1.001      0.536-1.869   0.998                               
   BMI (kg/m^2^)                                     0.985      0.956-1.015   0.334                               
   ASA score (1-2/3-4)                               0.957      0.355-2.580   0.931                               
   Comorbidity (yes/no)                              1.382      0.696-2.742   0.355                               
  Pathologic factors                                                                                              
   Tumor size (cm)                                   1.112      0.679-21487   0.687                               
   T stage (1-2/3-4)                                 1.148      0.293-4.497   0.843                               
   Nodal metastasis (yes/no)                         1.109      0.597-2.058   0.744                               
  Perioperative factors                                                                                           
   Operation type (PD/DP)                            0.838      0.439-1.601   0.593                               
   Operation method (open/MIS)                                                                                    
   Operation time (minutes)                          1.003      1.000-1.005   0.031   0.999         0.995-1.002   0.532
   Intraoperative bleeding (mL)                      1.001      1.000-1.002   0.054   1.001         0.999-1.002   0.292
   Perioperative transfusion (yes/no)                1.164      0.570-2.375   0.677                               
   Postoperative major complication (yes/no)         0.229      0.051-1.021   0.053   0.299         0.065-1.372   0.121
  Postoperative factors                                                                                           
   *Phellinus linteus* medication (yes/no)           2.273      1.151-4.492   0.018   2.141         1.039-4.411   0.039
   *Phellinus linteus* medication duration (weeks)   1.014      0.971-1.058   0.532                               

Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index; CI, confidence interval; DP, distal pancreatectomy; MIS, minimally invasive surgery; OR, odds ratio; PD, pancreaticoduodenectomy; PDAC, pancreatic ductal adenocarcinoma.

Association Between PL Medication and Adherence to Adjuvant Treatment {#section13-1534735418816825}
---------------------------------------------------------------------

In subgroup analysis, PL medication contributed to improved adherence to adjuvant chemotherapy regarding reduction of chemotherapy toxicity less than grade 3 complications (PL vs no PL medication: 14.7% vs 33.8%, *P* = .001), completion of chemotherapy without dose reduction, or incomplete stop (PL vs no PL medication: 83.8% vs 63.2%, *P* = .005), even after propensity score matching ([Figure 3](#fig3-1534735418816825){ref-type="fig"}, [Table 3](#table3-1534735418816825){ref-type="table"}). Disease-free survival (DFS) and overall survival (OS) of the PL medication group were significantly higher than the no PL medication group in patients with adjuvant treatment after curative resection (DFS; PL vs no PL medication 33 vs 12 months, *P* = .038, OS: PL vs no PL medication 39 vs 18 months, *P* = .012) ([Figure 4](#fig4-1534735418816825){ref-type="fig"}).

![Prescription details of *Phellinus linteus* (a, b, c), and effects of adjuvant treatment after curative resection of pancreatic ductal adenocarcinoma (PDAC) (d, e).](10.1177_1534735418816825-fig3){#fig3-1534735418816825}

###### 

Cliniopathologic Factors and Detailed Outcomes of Adjuvant Treatment in PL and No PL Medication Group in Adjuvant Treatment Group With Propensity Score Matching.

![](10.1177_1534735418816825-table3)

  Variables                                                                                  Adjuvant Treatment Group (n = 161)   Propensity Score--Matched Group (n = 136)                                                         
  ------------------------------------------------------------------------------------------ ------------------------------------ ------------------------------------------- ------------ -------------------- ------------------- ------
  Patient characteristics                                                                                                                                                                                                           
   Age (years)                                                                               62.9 ± 8.9                           61.9 ± 9.3                                  .469         62.9 ± 8.9           61.7 ± 9.7          .434
   Sex (male, %)                                                                             47.1%                                68.8%                                       .006         47.1%                61.1%               .055
   BMI (kg/m^2^)                                                                             25.1 ± 17.4                          22.5 ± 3.3                                  .185         25.1 ± 17.4          22.6 ± 3.5          .268
   ASA score (1/2/3/4, %)                                                                    24.2/50.0/22.7/1.5                   20.4/63.4/16.1/0                            .271         24.2/50.0/22.7/1.5   19.1/64.7/16.2/0    .346
   Comorbidity (%)                                                                           82.4%                                79.6%                                       .691         82.4%                80.9%               .925
  Perioperative factors                                                                                                                                                                                                             
   Pancreatioduodenectomy/distal pancreatectomy                                              36/32                                49/44                                       .609         36/32                35/33               .958
   Operation time (minutes)                                                                  390.1 ± 117.1                        350.7 ± 147.9                               .073         390.1 ± 117.1        364.1 ± 132.7       .136
   Combined resection (%)                                                                    30.9%                                23.7%                                       .368         30.9%                25.0%               .567
   R status (R0/R1/R2, %)                                                                    80.9/14.7/4.4                        82.8/16.1/1.1                               .401         80.9/14.7/4.4        79.4/19.1/1.5       .496
   Bleeding (cm^3^)                                                                          591.3 ± 384.1                        571.1 ± 474.3                               .778         591.3 ± 384.1        574.4 ± 504.1       .832
   Transfusion (%)                                                                           20.9%                                22.0%                                       .515         20.9%                21.8%               .544
  Pathologic factors                                                                                                                                                                                                                
   Tumor size (cm)                                                                           2.7 ± 1.0                            3.1 ± 1.3                                   .048         2.7 ± 1.0            3.0 ± 1.2           .104
   Pathologic T stage (T1/T2/T3/T4, %)                                                       1.5/1.5/92.6/4.4                     0/2.2/97.8/0                                .589         1.5/1.5/92.6/4.4     0/1.5/98.5/0        .741
   Pathologic N stage (N0/N1, %)                                                             72.1%                                60.2%                                       .134         72.1%                62.5%               .284
   Cell differentiation (%)                                                                                                                                                                                                         
  Well/moderate/poor/undifferentiated                                                        11.9/82.1/4.5/1.5                    17.6/70.3/11.0/1.1                          .314         11.9/82.1/4.5/1.5    16.2/73.5/8.8/1.5   .636
   Retrieved lymph node                                                                      19.7 ± 11.5                          18.8 ± 12.9                                 .634         19.7 ± 11.5          19.2 ± 11.7         .791
   Positive lymph node                                                                       2.0 ± 2.1                            1.9 ± 2.8                                   .791         2.0 ± 2.1            2.6 ± 3.0           .213
   Perineural invasion                                                                       73.5%                                66.3%                                       .387         73.5%                66.2%               .445
   Lymphovascular invasion                                                                   41.2%                                35.9%                                       .514         41.2%                39.7%               .721
   Adjust organ invasion                                                                     16.2%                                21.5%                                       .426         16.2%                23.5%               .391
   Postoperative major complication^[a](#table-fn4-1534735418816825){ref-type="table-fn"}^   16.7%                                13.4%                                       .621         16.7%                10.0%               .395
   Hospital stay (days)                                                                      18.0 ± 9.4                           19.9 ± 36.3                                 .643         18.0 ± 9.4           19.8 ± 13.2         .845
  Detailed outcomes of adjuvant treatment                                                                                                                                                                                           
   Time interval from resection to adjuvant treatment (days)                                 60.8 ± 34.2                          46.9 ± 24.7                                 .004         60.8 ± 34.2          46.3 ± 27.1         .009
   Adjuvant treatment regimen                                                                                                                                                                                                       
    Chemoradiation                                                                           18 (26.5%)                           21 (22.6%)                                  .457         18 (26.5%)           17 (25%)            .898
    Chemotherapy only                                                                        50 (73.5%)                           72 (77.4%)                                  50 (73.5%)   51 (75%)                                 
   Radiation dose (range, Gy)                                                                40.5 ± 15.5                          41.3 ± 12.2                                 .885         40.5 ± 15.5          40.8 ± 13.8         .628
   Chemotherapy regimen                                                                                                                                                                                                             
    Gemcitabine base                                                                         47 (69.1%)                           61 (65.5%)                                  .728         47 (69.1%)           42 (61.8%)          .345
    5-FU base                                                                                21 (30.9%)                           32 (34.5%)                                  21 (30.9%)   26 (38.2%)                               
   Chemotherapy toxicity (%)                                                                                                                                                                                                        
    ≥Grade 3 toxicity                                                                        10 (14.7%)                           24 (25.8%)                                  .026         10 (14.7%)           23 (33.8%)          .001
   Result of chemotherapy (%)                                                                                                                                                                                                       
    Completion                                                                               57 (83.8%)                           64 (68.8%)                                  .027         57 (83.8%)           43 (63.2%)          .005
    Dose reduction                                                                           6 (8.8%)                             13 (14.0%)                                  6 (8.8%)     10 (14.7%)                               
    Stop                                                                                     5 (7.4%)                             16 (17.2%)                                  5 (7.4%)     15 (22.1%)                               

Abbreviations: 5-FU, fluorouracil; ASA, American Society of Anesthesiologists; BMI, body mass index; PL, *Phellinus linteus*.

Postoperative major complication includes more than Clavien-Dindo classification grade III.

![Survival analysis of propensity matched population on *Phellinus linteus* (PL) medication, with or without adjuvant treatment, after curative resection.](10.1177_1534735418816825-fig4){#fig4-1534735418816825}

Discussion {#section14-1534735418816825}
==========

Current evidence indicates that adherence and completion of adjuvant treatment for the duration of planned schedules, rather than for a short interval between surgery and adjuvant chemotherapy, is crucial for improving survival outcomes in patients who underwent radical pancreatectomy with curative intent.^[@bibr7-1534735418816825],[@bibr10-1534735418816825]^ Identifying specific clinical factors affecting completion of chemotherapy, therefore, is mandatory for improving survival outcomes in patients who underwent radical pancreatectomy for pancreatic cancer. However, there seems to be few studies to investigate this issue.

Postoperative complications after radical pancreatectomy frequently develop^[@bibr11-1534735418816825][@bibr12-1534735418816825]-[@bibr13-1534735418816825]^ and are a major cause of delay or failure of adjuvant treatment, due to the poor general condition of patients.^[@bibr13-1534735418816825][@bibr14-1534735418816825]-[@bibr15-1534735418816825]^ Major complications, including especially postoperative pancreatic fistula and postpancreatectomy hemorrhage, induce life-threatening conditions and hinder postoperative recovery after curative resection of pancreatic cancer.^[@bibr16-1534735418816825][@bibr17-1534735418816825][@bibr18-1534735418816825]-[@bibr19-1534735418816825]^ Our data also showed that perioperative bleeding and postoperative complications are correlated with completion of adjuvant treatment after curative resection for pancreatectomy. Interestingly, PL medication after curative resection for pancreatic cancer was a significant prognostic factor for completion of adjuvant chemotherapy.

There is substantial evidence demonstrating the antitumor effects of PL based on in vitro and in vivo experiments.^[@bibr20-1534735418816825],[@bibr21-1534735418816825]^ Despite the potential of PL medication as an anticancer treatment, few clinical studies have been published regarding the medication.^[@bibr8-1534735418816825],[@bibr22-1534735418816825]^ There have been no prior publications regarding well-designed clinical studies analyzing the anticancer effects of PL medication in pancreatic cancer. This study revealed that PL medication promotes adherence to adjuvant treatment by reducing the rate at which patients reduce their dose or cease adjuvant chemotherapy. The exact underlying mechanism needs to be further investigated; however, this protective effect of PL medication in the setting of adjuvant therapy might be due to its action in reducing clinically relevant chemotherapy-related toxicities in the postoperative period after radical pancreatectomy.

Although this study used propensity score--matched comparisons, a limitation of this study is the retrospective and single institutional study. External validation in large cohorts would be necessary to verify the results of this study regarding oncologic effects of PL medication. In addition, a well-designed randomized control trial study is necessary for confirming antitumor, immune promoting or toxicity reduction effects of PL medication in the postoperative period following radical pancreatectomy.

In conclusion, PL medication contributed to improved survival by increasing adherence to chemotherapy in the group with adjuvant treatment. Oncologic effects of PL medication appear to be due to its action in lowering the toxicity of chemotherapy, according to our retrospective cohort analysis. Considering the limited literature on methods to improve adherence to postoperative chemotherapy in patients with radical pancreatectomy for pancreatic cancer, the findings of this study suggest the value in conducting randomized control studies to further evaluate and confirm this hypothesis.
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